Copenhagen - Delayed Quote DKK

H. Lundbeck A/S (HLUN-B.CO)

29.58

+0.02

+(0.07%)

At close: April 25 at 4:59:44 PM GMT+2

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.1 Brexpiprazole was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.4

PR Newswire last month

HLBBF

HLUBF
Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal

Danish pharmaceutical company Lundbeck will buy Longboard Pharmaceuticals (LBPH) in a deal valued at $2.6 billion, with the former hoping to build off of its pipeline of epilepsy drug treatment. Market Domination hosts Julie Hyman and Josh Lipton take a closer look at the details of the deal. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 6 months ago

HLBBF

HLUBF

LBPH

Performance Overview

Return	HLUN-B.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-26.59%	--
1-Year	-6.84%	-15.32%
3-Year	-18.74%	-9.40%